<DOC>
	<DOCNO>NCT00162097</DOCNO>
	<brief_summary>The purpose study ass steady-state pharmacokinetics ( PK ) efavirenz ( EFV ) human immunodeficiency virus type 1 ( HIV-1 ) infect subject stable antiretroviral regimen contain EFV , select degree hepatic impairment normal hepatic function .</brief_summary>
	<brief_title>Pharmacokinetics Efavirenz HIV-1 Infected Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>HIV1 infection without Hepatitis B C infection Stable antiretroviral regimen contain efavirenz nucleoside/nucleotide reverse transcriptase inhibitor ( NRTI ) least 1 month Mild , moderate severe hepatic impairment hepatic cirrhosis Acute flare hepatitis Positive pregnancy test female Significant acute medical illness past 2 month Use agent know significantly affect liver metabolism Change medication treat chronic disease past 2 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>